Alumis Inc
ALMS26.190USD
-0.150-0.57%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.73BMarket Cap
LossP/E TTM
More Details of Alumis Inc Company
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Alumis Inc Info
Ticker SymbolALMS
Company nameAlumis Inc
IPO dateJun 28, 2024
CEOBabler (Martin)
Number of employees168
Security typeOrdinary Share
Fiscal year-endJun 28
Address280 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502316625
Websitehttps://www.alumis.com/
Ticker SymbolALMS
IPO dateJun 28, 2024
CEOBabler (Martin)
Company Executives of Alumis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Dr. David M. Goldstein, Ph.D.
Dr. David M. Goldstein, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Ms. Sara Klein
Ms. Sara Klein
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
2.07M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Other
61.97%
Shareholders
Shareholders
Proportion
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Other
61.97%
Shareholder Types
Shareholders
Proportion
Private Equity
32.11%
Investment Advisor
11.33%
Hedge Fund
9.51%
Venture Capital
7.36%
Investment Advisor/Hedge Fund
5.96%
Research Firm
0.67%
Individual Investor
0.66%
Bank and Trust
0.07%
Insurance Company
0.02%
Other
32.32%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
211
79.11M
81.97%
+900.81K
2025Q3
210
78.21M
82.24%
-347.38K
2025Q2
186
78.54M
55.16%
+26.45M
2025Q1
129
40.48M
86.71%
-471.52K
2024Q4
110
40.33M
76.60%
+5.09M
2024Q3
85
35.23M
67.43%
+3.39M
2024Q2
30
30.28M
0.00%
+30.28M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foresite Capital Management, LLC
10.61M
10.91%
+580.09K
+5.79%
Nov 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.57%
-1.00
-0.00%
Sep 30, 2025
Samsara BioCapital, LLC
5.13M
5.28%
+333.62K
+6.95%
Nov 20, 2025
VenBio Partners LLC
4.62M
4.75%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.03M
4.15%
+625.40K
+18.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.79M
3.9%
-17.42K
-0.46%
Sep 30, 2025
Nextech Invest, Ltd.
2.92M
3%
--
--
Sep 30, 2025
Cormorant Asset Management, LP
2.15M
2.21%
--
--
Sep 30, 2025
SR One Capital Management, LP
1.96M
2.02%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
1.93M
1.98%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
